Proton beam therapy for hepatocellular carcinoma

Area of Science:

• Hepatobiliary cancers
• Radiation oncology
• Advanced radiotherapy techniques

Background:

• Hepatocellular carcinoma (HCC) treatment often involves radiation therapy, but its use is limited by risks of liver toxicity (hepatotoxicity) and a lack of robust clinical trial data.
• Current radiotherapy techniques can lead to significant toxicity, influenced by baseline liver function and radiation dose to healthy liver tissue.

Purpose of the Study:

• To review the clinical rationale for utilizing proton beam therapy (PBT) in HCC patients.
• To evaluate clinical outcomes and toxicity data from existing PBT studies for HCC.
• To discuss technical challenges and patient selection criteria for PBT in HCC.

Main Methods:

• Review of retrospective and prospective studies on PBT for HCC.
• Analysis of clinical outcomes including local control and overall survival.
• Assessment of toxicity profiles and comparison with photon-based therapies.

Main Results:

• Promising results reported for PBT in HCC regarding local control, overall survival, and toxicity.
• PBT's dosimetric properties may spare more liver volume, potentially reducing hepatotoxicity.
• PBT may enable dose escalation to the tumor, improving treatment efficacy.

Conclusions:

• PBT demonstrates encouraging outcomes for liver cancer treatment.
• Further research, including randomized trials, is essential to establish PBT's superiority over conventional photon therapy.
• Identifying optimal patient selection criteria will maximize PBT benefits for HCC.